Healthy Participants Clinical Trial
— REVIAGEOfficial title:
Tolerance of an Immersive Virtual Reality Task Evaluating the Spatial Memory of Elderly Subjects and the Effects of Age, Gender and Level of Education on Performance
Verified date | June 2024 |
Source | Hospices Civils de Lyon |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Spatial navigation is a high-level cognitive function allowing animals and humans to orient and move in space by constructing a mental representation of the environment. This function has been identified as one of the very first to be affected by Alzheimer's disease, including at the early stages, before the appearance of other mnesic disorders that the latter causes, such as those of episodic memory. However, the neuropsychological tests currently used in the diagnosis of cognitive disorders do not allow effective assessment of spatial memory impairment, in particular because it is impractical to offer spatial orientation tasks in a consulting room. In this context, virtual reality offers very interesting perspectives: it makes it possible to create controlled environments to assess spatial memory, without leaving the place of consultation. Before being able to test its possible diagnostic efficacy, it is imperative to test the feasibility as well as the reliability of this type of task on an elderly population with no cognitive impairment. The data currently available on immersion tolerance in virtual reality mainly concern young people aged 18 to 35 and little data is available concerning the elderly or very old. If this task correctly assesses spatial navigation abilities, this study should find the effects of age and sex usually observed. The aim of this study is to assess the tolerance of an immersive virtual reality task evaluating the spatial memory of elderly subjects and the effects of age, gender and level of education on performance.
Status | Completed |
Enrollment | 84 |
Est. completion date | May 28, 2024 |
Est. primary completion date | May 28, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 60 Years to 85 Years |
Eligibility | Inclusion Criteria: - Participant aged 60 to 85 - Participant affiliated or entitled to a social security scheme - Recruited participants must have been informed and consented in writing Exclusion Criteria: - Participant with a diagnosis of cognitive impairment - Severe, progressive or unstable pathology whose nature may interfere with the evaluation variables (epilepsy, psychiatric or psychotic disorders in the acute phase, visual hallucinations, acute infection, lack of sleep) - Participant equipped with a pacemaker - Burns or sores on the upper part of the face or on the scalp - Consumption of toxic substances that can influence cognitive performance - Deafness or blindness that may compromise participant assessment or completion of tasks and scales - Participant under guardianship or curatorship or legal safeguard - Participant refusing to use an immersive virtual reality tool - Criterion for stopping the procedure under study: stopping the virtual reality task due to the participant's simulator sickness. - Montreal Cognitive Assessment (MOCA) score less than 26 - MacNair Subjective Complaint Scale score greater than 16 - AGGIR score (Autonomy, Gerontology Group Iso Resources) less than 5 |
Country | Name | City | State |
---|---|---|---|
France | Charpennes Geriatric Hospital, Lyon University Hospital | Villeurbanne |
Lead Sponsor | Collaborator |
---|---|
Hospices Civils de Lyon |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sickness Simulator Questionnaire (SSQ) score | This is a questionnaire composed of 16 items covering the potential symptoms of intolerance to a virtual reality tool.
Each item is rated 0 (no symptom), 1 (mild symptom), 2 (moderate symptom) or 3 (severe symptom). The total score is obtained by multiplying the sum of the items by 3.74, and therefore varies from 0 to 180. |
The sickness simulator scale is assessed immediately after the immersive virtual reality task. | |
Secondary | Time to complete the task in immersive virtual reality according to the age of the participants | Time to complete the task in immersive virtual reality (in seconds) according to the age of participants (in years) | through study completion, 1 year | |
Secondary | Time to complete the task in immersive virtual reality (in seconds) according to the gender of participants (male or female) | Time to complete the task in immersive virtual reality according to the gender of participants | through study completion, 1 year | |
Secondary | Time to complete the task in immersive virtual reality according to the number of years of study | Time to complete the task in immersive virtual reality (in seconds) according to the number of years of study (from entry into primary school) | through study completion, 1 year | |
Secondary | Raw score on the Wechsler Memory Scale-III (MEM III) Spatial Memory subtest | The test is designed for adults and the elderly to assess the performance of auditory memory, visual memory, memory immediate, delayed and visual working memory.The subtest used is the Spatial Memory subtest, it ranges from 0 to 28 (the higher the score, the better the performance). | through study completion, 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05445440 -
A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine
|
Phase 1 | |
Completed |
NCT03712540 -
An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants
|
Phase 1 | |
Completed |
NCT03649165 -
A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT05956002 -
A Study to Evaluate the Study Medication (Etrasimod) When Mixed With Food in Healthy Participants
|
Phase 1 | |
Completed |
NCT05539976 -
A Taste Assessment of Iberdomide and Mezigdomide in Healthy Participants
|
||
Withdrawn |
NCT04558216 -
Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy Participants
|
Phase 1 | |
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT06097390 -
A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III
|
Phase 1 | |
Completed |
NCT05546151 -
A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent
|
Phase 1 | |
Completed |
NCT05056246 -
Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants
|
Phase 1 | |
Completed |
NCT04390776 -
Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.
|
Phase 1 | |
Completed |
NCT05074459 -
A Study in Healthy Adults Investigating Eptinezumab Produced by 2 Different Manufacturing Cell Lines
|
Phase 1 | |
Enrolling by invitation |
NCT06089109 -
Creating VIP Corps to Reduce Maternal Deaths
|
N/A | |
Completed |
NCT03278080 -
Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #1
|
N/A | |
Completed |
NCT05064800 -
PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants
|
Phase 1 | |
Completed |
NCT04471298 -
A Study of Qishenyiqi Dripping Pills in Healthy Participants
|
Phase 1 | |
Completed |
NCT04914936 -
A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196
|
Phase 1 | |
Completed |
NCT01681186 -
A Study of LY2940680 in Healthy Participants
|
Phase 1 | |
Completed |
NCT02882386 -
Amino Acid Kinetics in Blood After Consuming Different Milk Protein Supplements
|
N/A | |
Completed |
NCT02563262 -
Human Neutral Body Posture in Weightlessness
|
N/A |